Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1999 1
2000 3
2001 4
2002 8
2003 4
2004 7
2005 7
2006 7
2007 4
2008 5
2009 5
2010 4
2011 6
2012 6
2013 14
2014 19
2015 8
2016 15
2017 11
2018 8
2019 11
2020 13
2021 23
2022 12
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Results by year

Filters applied: . Clear all
Page 1
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Herrera AF, Lin J, Kim E, Chakraborty S, Marinello P, Moskowitz CH. Armand P, et al. Among authors: vassilakopoulos tp. Blood. 2023 Sep 7;142(10):878-886. doi: 10.1182/blood.2022019386. Blood. 2023. PMID: 37319435 Free PMC article.
Hodgkin lymphoma: Introduction.
Engert A, Vassilakopoulos TP. Engert A, et al. Among authors: vassilakopoulos tp. Semin Hematol. 2016 Jul;53(3):137-8. doi: 10.1053/j.seminhematol.2016.05.001. Epub 2016 May 12. Semin Hematol. 2016. PMID: 27496303 No abstract available.
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Kim E, Nahar A, Balakumaran A, Moskowitz CH. Chen R, et al. Among authors: vassilakopoulos tp. Blood. 2019 Oct 3;134(14):1144-1153. doi: 10.1182/blood.2019000324. Epub 2019 Aug 13. Blood. 2019. PMID: 31409671 Free PMC article. Clinical Trial.
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH; KEYNOTE-087. Chen R, et al. Among authors: vassilakopoulos tp. J Clin Oncol. 2017 Jul 1;35(19):2125-2132. doi: 10.1200/JCO.2016.72.1316. Epub 2017 Apr 25. J Clin Oncol. 2017. PMID: 28441111 Free PMC article. Clinical Trial.
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho JM, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos TP, Warzocha K, McCarthy D, Ma X, Corona K, Saint-Martin JR, Chang H, Landesman Y, Joshi A, Wang H, Shah J, Shacham S, Kauffman M, Van Den Neste E, Canales MA. Kalakonda N, et al. Among authors: vassilakopoulos tp. Lancet Haematol. 2020 Jul;7(7):e511-e522. doi: 10.1016/S2352-3026(20)30120-4. Lancet Haematol. 2020. PMID: 32589977 Free article. Clinical Trial.
Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma.
Briest F, Noerenberg D, Hennch C, Yoshida K, Hablesreiter R, Nimo J, Sasca D, Kirchner M, Mansouri L, Inoue Y, Wiegand L, Staiger AM, Casadei B, Korkolopoulou P, Weiner J, Lopez-Guillermo A, Warth A, Schneider T, Nagy Á, Klapper W, Hummel M, Kanellis G, Anagnostopoulos I, Mertins P, Bullinger L, Rosenquist R, Vassilakopoulos TP, Ott G, Ogawa S, Damm F. Briest F, et al. Among authors: vassilakopoulos tp. Leukemia. 2023 Nov;37(11):2237-2249. doi: 10.1038/s41375-023-02013-9. Epub 2023 Aug 30. Leukemia. 2023. PMID: 37648814 Free PMC article.
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes.
Noerenberg D, Briest F, Hennch C, Yoshida K, Hablesreiter R, Takeuchi Y, Ueno H, Staiger AM, Ziepert M, Asmar F, Locher BN, Toth E, Weber T, Amini RM, Klapper W, Bouzani M, Poeschel V, Rosenwald A, Held G, Campo E, Ishaque N, Stamatopoulos K, Kanellis G, Anagnostopoulos I, Bullinger L, Goldschmidt N, Zinzani PL, Bödör C, Rosenquist R, Vassilakopoulos TP, Ott G, Ogawa S, Damm F. Noerenberg D, et al. Among authors: vassilakopoulos tp. J Clin Oncol. 2024 Feb 1;42(4):452-466. doi: 10.1200/JCO.23.01053. Epub 2023 Dec 6. J Clin Oncol. 2024. PMID: 38055913
Treatment of splenic marginal zone lymphoma.
Kalpadakis C, Pangalis GA, Angelopoulou MK, Vassilakopoulos TP. Kalpadakis C, et al. Among authors: vassilakopoulos tp. Best Pract Res Clin Haematol. 2017 Mar-Jun;30(1-2):139-148. doi: 10.1016/j.beha.2016.07.004. Epub 2016 Nov 4. Best Pract Res Clin Haematol. 2017. PMID: 28288709 Review.
Prognostic factors in Hodgkin lymphoma.
Bröckelmann PJ, Angelopoulou MK, Vassilakopoulos TP. Bröckelmann PJ, et al. Among authors: vassilakopoulos tp. Semin Hematol. 2016 Jul;53(3):155-64. doi: 10.1053/j.seminhematol.2016.05.003. Epub 2016 May 12. Semin Hematol. 2016. PMID: 27496306 Review.
190 results